Ibrutinib Combined With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results From the Randomized Phase 3 SYMPATICO Study

News
Video

Michael Wang, MD, presents the primary analysis results from the multinational, randomized, double-blind, phase 3 SYMPATICO study comparing ibrutinib plus venetoclax vs ibrutinib plus placebo in patients with relapsed/refractory mantle cell lymphoma (R/R MCL).

Related Videos
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
William B. Pearse, MD
William B. Pearse, MD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Andre Goy, MD
Tycel Phillips, MD
Related Content
Michael Wang, MD

Frontline Acalabrutinib Plus Chemoimmunotherapy Elicits Meaningful Survival Benefit in MCL

May 2nd 2024
Article
Lori A. Leslie, MD

FDA Approval Insights: Pirtobrutinib in MCL

February 27th 2023
Podcast
stock.adobe.com

B-Cell Receptor Signaling Activity Portends Inferior Outcomes in MCL

April 17th 2024
Article
Joshua Brody, MD

Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL

December 8th 2022
Podcast
Dr Ann Tivey

Observational Study Shows Frontline Ibrutinib With/Without Rituximab Is Safe and Effective in Low-Risk Mantle Cell Lymphoma

March 28th 2024
Article
Cancer in the blood outbreak and treatment for malignant cells in a human body caused by carcinogens and genetics with a cancerous cell as an immunotherapy and leukemia or lymphoma symbol and medicalImage Credit: © freshidea - stock.adobe.com

Brexu-Cel Displays Superior Responses vs Pirtobrutinib in Relapsed/Refractory MCL Matching-Adjusted Indirect Comparison

March 22nd 2024
Article